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Abstract 
Cytoplasmic expression of claudin-1 in metastatic melanoma cells correlates to increased 
migration, and increased secretion of MMP-2 in a PKC dependent manner, whereas 
claudin-1 nuclear expression is found in benign nevi. Melanoma cells were transfected with a 
vector expressing CLDN-1 fused to a nuclear localization signal (NLS). Despite significant 
nuclear localization of claudin-1, there was still transport of claudin-1 to the cytoplasm. 
Phorbol ester treatment of cells transfected with NLS-claudin-1 resulted in an exclusion of 
claudin-1 from the nucleus, despite the NLS. To ascertain whether PKC or PKA were in-
volved in this translocation, we mutated the putative phosphorylation sites within the pro-
tein. We found that mutating the PKC phosphorylation sites to mimic a non-phosphorylated 
state did not cause a shift of claudin-1 to the nucleus of the cells, but mutating the PKA sites 
did. Mutations of either site to mimic constitutive phosphorylation resulted in cytoplasmic 
claudin-1 expression. Stable claudin-1 transfectants containing non-phosphorylatable PKA 
sites exhibited decreased motility. These data imply that subcellular localization of claudin-1 
can be controlled by phosphorylation, dicating effects on metastatic capacity. 
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Introduction 
Claudin-1 is a member the claudin family of 
proteins, which are important in tight junction forma-
tion (1). Tight junction proteins are located along the 
cell membrane at the apical edges. They play roles in 
major cellular functions such as growth and adhesion 
and are responsible for regulating the paracellular 
transport of molecules (2). Claudins were first shown 
to be abnormally expressed in breast and ovarian 
cancer (3), and have since been found to play roles in 
other cancers such as melanoma (4), renal and 
squamous cell carcinomas (2), to name just a few. Be-
cause claudins regulate paracellular transport, they 
are usually found at the cell membrane. However, 
these proteins, and other tight junction proteins such 
as zona occludens-1 (ZO-1) have been shown to alter 
their subcellular localization during malignant pro-
gression (5). In melanocytic lesions, we have shown 
that claudin-1 expression is not only increased, but 
that its subcellular localization becomes dysregulated, 
moving away from its typical location at the cell 
membrane (4). Benign lesions and less aggressive 
melanomas express claudin-1 in the nucleus, whereas Int. J. Med. Sci. 2009, 6 
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aggressive melanomas have an abundance of 
claudin-1 in the cytoplasm. We have shown that in-
creasing claudin-1 expression in less metastatic 
melanoma cells caused an increase in melanoma cell 
motility, as well as in levels of MMP-2 activation and 
secretion. These effects could be reversed using 
siRNA directed against claudin-1. Increased claudin-1 
expression did not correlate to increases in tight junc-
tion function, presumably due to the fact that it was 
expressed in the cytoplasm, rather than solely at the 
cell membrane (4).  
Other studies have shown that protein kinase 
activity is important for the regulation and localiza-
tion of claudin expression. It has been shown that 
protein kinases such as Protein Kinase A (PKA) and 
Protein Kinase C (PKC) can phosphorylate claudins 
(6,7). Phorbol ester treatment, which activates con-
ventional PKC isoforoms, increased the expression (8) 
and cytoplasmic distribution of claudin-1, and simul-
taneously reduced tight junction barrier integrity (7). 
Conversely, activation of atypical PKC isoforms using 
bryostatin instead increased the expression of 
claudin-1 in the tight junction complex, and increased 
tight junction barrier integrity (9). In melanoma, we 
have shown that claudin-1 expression levels are in-
creased upon phorbol ester treatment, and decreased 
by inhibitors of conventional PKC isoforms, implying 
that, in melanoma, claudin-1 expression is dependent 
upon PKC isoforoms such as α, β and γ (4). In this 
study, we also examine the effects of PKA on 
claudin-1 expression and localization, and how the 
localization of claudin-1 can affect melanoma cell mo-
tility.  
Significance 
Tight junction proteins have long been thought 
to be solely responsible for the transport of paracel-
lular molecules. Recent data from cancer studies in-
dicate that these proteins also play important roles in 
signal transduction. In part, this is facilitated by the 
translocation of claudins to subcellular locations other 
than their “normal” location at the cell membrane. We 
show here that phosphorylation modifications of the 
tight junction protein claudin-1 cause its translocation 
to the cytoplasm and nucleus and that the subcellular 
localization of claudin-1 may dictate the metastatic 
capacity of melanoma cells. Our findings suggest that 
nuclear versus cytoplasmic expression of claudin-1 
may become a valuable marker for diagnosis of ma-
lignant melanoma. 
Results 
PKC activation increases export of claudin-1 
from the nucleus. 
Nuclear localization of claudin-1 is evident in 
nevi, and less metastatic melanoma cells (4). To de-
termine if the nuclear localization of claudin-1 was 
related to the increased invasive capacity of mela-
noma cells, we created a claudin-1 expression vector 
expressing claudin-1 containing a nuclear localization 
signal (pDsRedCLDN1-NLS). However, transfection 
of this vector into G361 melanoma cells (which have 
low levels of claudin-1) resulted in both nuclear and 
cytoplasmic expression of claudin-1 (Figure 1 A) de-
spite the fact that claudin-1 was attached to a NLS. 
This led us to ask whether a post-translational modi-
fication such as phosphorylation might be resulting in 
the transport of claudin-1 out of the nucleus. Since we 
have previously implicated PKC in melanoma pro-
gression, and claudin-1 expression, we transfected 
pDsRedCLDN1-NLS into G361 cells, and then treated 
the transfected cells with phorbol ester (PMA). 
Treatment of cells with 200nM PMA resulted in an 
almost complete exclusion of claudin-1 from the nu-
cleus (Figure 1B). This implies that active PKC may 
exist in the nucleus of melanoma cells, and the pres-
ence of active PKC isoforms in the nuclei of many cell 
types has been confirmed (10-12). Staining of the G361 
cells with antibodies to phosphorylated PKC (α, β, γ) 
demonstrates that there is active PKC in melanoma 
cell nuclei as well (Figure 1C). Further, we performed 
immunoprecipitation studies using an antibody that 
binds to any protein that is a potential PKC substrate, 
followed by western analysis for claudin-1. In 
UACC647 melanoma cells which are highly metastatic 
and have high levels of claudin-1 (4), claudin-1 
co-immunoprecipitates with the PKC substrate anti-
body (Figure 1D). In the presence of PKC inhibitors, 
which we have previously demonstrated to decrease 
claudin-1 expression (4), there is a decrease in the 
levels of claudin-1 precipitated by the PKC substrate 
antibody. G361 cells, which have very little endoge-
nous claudin-1, and low levels of PKC, show no im-
munoprecipitation of claudin-1 with the PKC sub-
strate antibody (Figure 1D). These data indicated that 
claudin-1 is a likely target for PKC phosphorylation. 
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Figure 1. Claudin-1 is not expressed solely in the nucleus even when under the direction of a nuclear localization 
signal. A) Cytoplasmic and nuclear extracts of G361 melanoma cells (low claudin-1 expressers) were transfected with wild 
type CLDN1 (CLDN1). By Western analysis, these transfectants demonstrate the presence of claudin-1 protein in the 
cytoplasm, with small amounts in the nucleus. When cells are transfected with CLDN1 under the control of a nuclear 
localization signal (CLDN1-NLS), there is increased expression of claudin-1 in the nucleus, but there are still large amounts 
of claudin-1 in the cytoplasm as well. B) All of the claudin-1 in the nucleus can be shuttled into the cytoplasm by treatment 
with the PKC activator PMA (phorbol ester). C) This implies that active PKC may exist in the nucleus of melanoma cells, so 
cells were stained with an antibody to pan-PO4-PKC. Confocal microscopy demonstrates that active PKC can be found in 
the nucleus of G361 melanoma cells. D) To determine if claudin-1 was a potential PKC substrate, cell lysates from claudin-1 
high UACC647 cells, and claudin-1 low G361 cells were subjected to immunoprecipitation using a PKC substrate antibody, 
and western analysis for claudin-1 was performed. GO6983, a PKC inhibitor, decreases the amount of claudin-1 that is 
immunoprecipitated by the PKC substrate antibody. G361 cells have very little claudin-1 and thus, none is precipitated by 
the PKC substrate antibody, indicating the specificity of this immunoprecipitation.  Int. J. Med. Sci. 2009, 6 
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PKC and PKA play distinct roles in the expres-
sion and localization of claudin-1 
To better characterize the phosphorylation of 
claudin-1 by PKC, we performed an in silico analysis 
of the putative PKC phosphorylation sites for 
claudin-1. We found that there are five putative PKC 
phosphorylation sites on the claudin-1 protein (212 
amino acids long), but all of these are also sites of PKA 
phosphorylation (Table 1). There are however, three 
unique sites of PKA phosphorylation, at amino acid 
residues 65-69, and 189-192 and 201-205. It should be 
noted that the aa189-192 site overlaps with a 
PKC/PKA phosphorylation site (aa188-191). To assess 
whether PKC or PKA was responsible for the phos-
phorylation and nuclear exclusion of claudin-1, we 
used site-directed mutagenesis of our 
PCDNA3.1-CLDN1 vector to make mutants that ei-
ther mimicked a constitutively phosphorylated state 
(conversion of the phosphorylation site to an aspartic 
acid residue, referred to as “D” mutants) or mutants 
that are non-phosphorylable (conversion of the phos-
phorylation site to an alanine residue, referred to as 
“A” mutants). This vector, when transfected into 
melanoma cells shows both cytoplasmic and nuclear 
expression of claudin-1, as compared to empty vector 
controls (Figure 2A). The sites of phosphorylation 
close to the end of the protein sequence (aa200-212) 
did not provide us with successful mutants. Muta-
tions to alanine in PKC/PKA sites did not affect the 
subcellular localization of claudin-1, but alanine mu-
tations of the two unique PKA sites caused nuclear 
localization of claudin-1 (Figure 2B). Mutations to 
aspartic acid in both PKA only as well as PKC/PKA 
sites caused cytoplasmic redistribution of claudin-1 
with complete exclusion from the nucleus (Figure 2C).   
Nuclear localization of claudin-1 upon mutation 
of the PKA sites could be mimicked using PKA in-
hibitors. Untreated M93-047 cells have high levels of 
claudin-1 and exhibit a diffuse, largely cytoplasmic 
pattern of claudin-1 (Figure 3A). Upon treatment with 
PKA inhibitors for 15 minutes, claudin-1 shuttles into 
the nucleus (Figure 3B). After 1 hour of treatment with 
PKA inhibitor, claudin-1 is still highly nuclear, al-
though some claudin-1 has started to shuttle out of 
the nucleus (Figure 3C). This is unlike the situation 
with PKC inhibitors, which cause a general down-
regulation of claudin-1 expression (4). Furthermore, it 
is interesting to note that all of the cell lines have 
similar levels of phospho-PKA (Figure 3D) which 
explains why the transfected claudin-1 is shuttled out 
of the nucleus even when transfected into less metas-
tatic G361 cells, which have low amounts of phos-
pho-PKC (4,13). Taken together these data indicate 
that PKA is likely contributing to the subcellular lo-
calization of claudin-1. 
Nuclear claudin-1 does not increase melanoma 
cell motility. 
We have previously shown that increasing the 
levels of CLDN-1 increases the invasion of melanoma 
cells (4). To determine if the increase in claudin-1 
needs to be cytoplasmic and not nuclear to affect the 
ability of melanoma cells to invade, we first per-
formed a stable transfection of our G361 cells with the 
S69A (PKA, non-phosphorylatable) claudin-1 mu-
tants. Pooled stable clones were analyzed for the ex-
pression of claudin-1 and its subcellular localization. 
As can be seen the PCDNA3.1-CLDN1 transfected 
cells have plenty of cytoplasmic claudin as compared 
to the stable empty vector clones (Figure 4A, B) 
whereas the S69A mutants have largely nuclear ex-
pression of claudin-1 (Figure 4C). To test their inva-
sive capacity, stable clones were allowed to invade 
through a Matrigel-coated invasion chamber. As 
compared to empty vector controls, cells transfected 
with the PKA deactivating S69A mutation did not 
show any increase in invasion. However, G361 cells 
transfected with the claudin-1 overexpressing vector 
showed a nearly 2-fold increase in invasion as com-
pared to the empty vector control (Figure 4D). These 
data appear to support the hypothesis that nuclear 
overexpression of claudin-1 does not increase the in-
vasive capacity of melanoma cells, where cytoplasmic 
expression of claudin-1 does.  
 
Table 1. Site-directed mutagenesis. Putative sites of PKC and PKA phosphorylation on the claudin-1 protein, and the 
primers used to perform site-directed mutagenesis of these sites. The first 10 rows represent mutations to alanine, and the 
last ten rows represent mutations to aspartic acid. 
AMINO ACID 
SEQUENCE 
MOTIF (PO4)  PKA/PKC  DNA BASE CHANGE  PRIMER 
31-34 RIYS  RXXpS PKA  T100G 
31-34 RIYS  [R/K]XX[pS/pT] PKC  T100G 
F: 5'-cagtggaggatttacgcctatgccggcgaca-3' 
R: 5'-tgtcgccggcataggcgtaaatcctccactg-3' 
65-69 KVFDS*  KXX[pS/pT] PKA  T205G  F:  5'-agtgcaaagtctttgacgccttgctgaatctgagc-3' 
R: 5'-gctcagattcagcaaggcgtcaaagactttgcact-3' 
188-190 RKT  [R/K]X[pS/pT] PKA  A568T  F:  5'-tgttcctgtccccgaaaatcaacctcttacccaac-3' Int. J. Med. Sci. 2009, 6 
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AMINO ACID 
SEQUENCE 
MOTIF (PO4)  PKA/PKC  DNA BASE CHANGE  PRIMER 
188-190 RKT  [R/K]X[pS/pT] PKC  A568T  R:  5'-gttgggtaagaggttgattttcggggacaggaaca-3' 
188-191 RKTT [R/K]XX[pS/pT] PKC  A571G 
188-191 RKTT [R/K][R/K]X[pS/
pT] 
PKA A571G 
F:5'-gctgttcctgtccccgaaaaacagcctcttacccaa-3' 
R:5'-ttgggtaagaggctgtttttcggggacaggaacagc-3' 
189-192 KTTS*  KXX[pS/pT] PKA  A568T_A571G  F:5'-ctgttcctgtccccgaaaatcagcctcttacccaacac-3' 
R:5'-gtgttgggtaagaggctgattttcggggacaggaacag-3' 
195-197 TPR  [pS/pT]X[R/K] PKA  A589G_G590C 
195-197 TPR  [pS/pT]X[R/K] PKC  A589G_G590C 
F:5'-aacaacctcttacccaacaccagcgccctatccaaaacc-3' 
R:5'-ggttttggatagggcgctggtgttgggtaagaggttgtt-3' 
31-34 RIYS  RXXpS PKA  T100G_C102A 
31-34 RIYS  [R/K]XX[pS/pT] PKC  T100G_C102A 
F:5'-gccccagtggaggatttacgcatatgccggcgaca-3' 
R:5'-tgtcgccggcatatgcgtaaatcctccactggggc-3' 
65-69 KVFDS  KXX[pS/pT] PKA  T205G_C206A 
 
F:5'-ccagtgcaaagtctttgacgacttgctgaatctgagcagc-3' 
R:5'-gctgctcagattcagcaagtcgtcaaagactttgcactgg-3' 
188-190 RKT  [R/K]X[pS/pT] PKA  A568G_C569A_A570C 
188-190 RKT  [R/K]X[pS/pT] PKC  A568G_C569A_A570C 
F:5'-ctttgctgttcctgtccccgaaaagacacctcttacccaacacca-3' 
R:5'-tggtgttgggtaagaggtgtcttttcggggacaggaacagcaaag-3' 
188-191 RKTT [R/K]XX[pS/pT] PKC  A571G_C572A 
188-191 RKTT [R/K][R/K]X[pS/
pT] 
PKA A571G_C572A 
F:5'-ttcctgtccccgaaaaacagactcttacccaacaccaagg-3' 
R:5'-ccttggtgttgggtaagagtctgtttttcggggacaggaa-3' 
189-192 KTTS KXX[pS/pT] PKA  A568G_C569A_A570C_
A571G_C572A 
F:5'-actttgctgttcctgtccccgaaaagacgactcttacccaacaccaaggccc-3' 
R:5'-gggccttggtgttgggtaagagtcgtcttttcggggacaggaacagcaaagt-3' 
195-197 TPR  [pS/pT]X[R/K] PKA  A589G_G590A_G591C 
195-197 TPR  [pS/pT]X[R/K] PKC  A589G_G590A_G591C 
F:5'-aaaacaacctcttacccaacaccagacccctatccaaaacctgca-3' 
R:5'-tgcaggttttggataggggtctggtgttgggtaagaggttgtttt-3' 
 
 
 
 
Figure 2. Site-directed mutagenesis 
of PKA/PKC in CLDN1. A) G361 
melanoma cells which have very little 
endogenous claudin-1 were transfected 
with either an empty vector or CLDN-1 
and localization was observed using 
confocal microscopy. Site directed 
mutagenesis was performed to render 
the potential sites of PKC and PKA 
phosphorylation on the claudin-1 pro-
tein non phosphorylatable or to mimic 
constitutive activation of PKC or PKA. 
B) Rendering the serine at position 69 
on the claudin-1 protein 
non-phosphorylatable causes nuclear 
localization of claudin-1. C) Mutations 
mimicking constitutive activation of its 
phosphorylatable sites cause exclusively 
cytoplasmic localizationof claudin-1. Int. J. Med. Sci. 2009, 6 
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Figure 3. Pharmacological deactivation of PKA also causes nuclear translocation of claudin-1. A) Claudin-1 high 
M93-047 cells have abundant expression of claudin-1 in the cytoplasm, with some nuclear expression of claudin-1. B) 
Treatment of these cells with PKA inhibitor results in nuclear translocation of claudin-1 in as little as 15 minutes, with C) 
sustained nuclear localization at 1 hour. D) All melanoma cell lines, regardless of claudin-1 status, or metastatic ability have 
similar levels of active PKA.  
 
Figure 4. Nuclear claudin-1 cannot increase 
the invasive ability of G361 melanoma cells. 
Stable transfectants of the empty vector (A), the 
PCDNA3.1-CLDN1 vector (B), and the 
PCDNA3.1-CLDN1 vector containing the S69A 
mutation (C) were created. These cells were 
then subjected to invasion through Matrigel in a 
modified Boyden chamber assay. Only the 
PCDNA3.1-CLDN1 stable transfectants dem-
onstrated an increase in invasion (D). 
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Discussion 
Claudin-1 has been shown to play an important 
role in skin development and tumorigenesis. 
Claudin-1 null mice die from dehydration within a 
few hours of birth due to the breakdown of barrier 
integrity in the epidermis (14). In humans, patients 
with the pathological condition known as AEC (An-
kyloblepharon–Ectodermal dysplasia–Clefting) also 
have compromised skin integrity, and this has been 
shown to correlate to the lack of claudin-1 and also to 
the loss of p63 (15). Further, we have previously 
shown that increasing claudin-1 expression increases 
melanoma metastasis (4). In this study we demon-
strate that the nuclear localization of claudin-1 cannot 
contribute to the migratory capacity of melanoma 
cells. These data confirm our previous observations 
that nuclear claudin-1 is expressed largely in benign 
nevi, and early stage melanoma, but that highly me-
tastatic melanoma cells tend to have increased 
claudin-1 in the cytoplasm and at the membrane, but 
very little nuclear staining (4). Further, we demon-
strate that claudin-1 subcellular localization is affected 
by PKA, although constitutively activating both PKA 
and PKC sites results in the cytoplasmic distribution 
of claudin-1. However, the deactivation of PKC sites 
does not cause nuclear localization of claudin-1. 
Unlike PKC, which we have previously shown to de-
crease the levels of claudin-1 expression, PKA inhibi-
tion does not appear to affect claudin-1 levels, but 
does cause nuclear sequestration of claudin-1, imply-
ing that PKA is required for claudin-1 exclusion from 
the nucleus. It is curious that in cases where claudin-1 
is low, it is predominantly nuclear, despite abundant 
active PKA. This observation implies that the levels of 
claudin-1 may need to reach a certain threshold prior 
to being shuttled out of the nucleus. Hence, in metas-
tatic melanoma cells that have high levels of PKC, 
there is increased claudin-1 expression, and when 
enough is expressed in the nucleus, PKA causes its 
translocation to the cytoplasm.  
It is unclear what the significance of claudin-1 in 
the nucleus may be. It is known that the nuclear ex-
pression of other tight junction proteins such as ZO-1 
can inhibit proliferation (16), but in our stable S69A 
transfectants, we see no difference in the rate of pro-
liferation between the transfectants with nuclear 
claudin-1 and the empty vector controls (data not 
shown). It has been suggested that the translocation of 
claudin-1 into the nucleus of cells, despite the absence 
of a nuclear localization signal may require APC, 
ZO-1 or ZO-2, possibly as shuttles for claudin-1 (17). 
This opens up the possibility that Wnt signaling is 
involved in claudin-1 expression and localization. 
Indeed, a study shows that increasing β-catenin in-
creases the expression of claudin-1 in colorectal cancer 
cells, and that claudin-1 expression is increased in 
more aggressive cancers (18). We have previously 
demonstrated the importance of the non-canonical 
Wnt signaling pathway in melanoma (13,19,20), and 
have shown that Wnt5A increases the epithelial to 
mesenchymal transition (EMT) in melanoma cells, 
leading to increased invasion (13). These effects all 
require PKC, and since we have shown that, in mela-
noma, claudin-1 expression is dependent upon PKC, 
it is likely that Wnt5A may also increase claudin-1 
expression. Studies to confirm this are underway in 
our laboratory. Further, claudin-1 is important in 
mediating an EMT in colon cancer cells (17), similar to 
that seen with Wnt5A. All of these data taken together 
imply that claudin-1 is an important marker of mela-
noma progression, especially when its subcellular 
localization is considered, as we have shown that its 
cytoplasmic expression is critical for increased ma-
lignancy. How it interacts with other molecules in-
volved in melanoma malignancy, such as members of 
the Wnt pathway, remains to be determined. 
Materials and Methods 
Cell lines. As previously described (4), the hu-
man melanoma cell lines UACC647 and M93-047 
were cultured in RPMI-1640 media (Gibco-BRL, Be-
thesda, MD) supplemented with 10% fetal bovine 
serum (FBS) (Hyclone, Logan, UT), 100 units/ml 
Penicillin G and 100 units streptomycin (Gibco-BRL). 
G361 cells were maintained in McCoy’s 5A medium 
(Gibco-BRL) with 10% FBS. All cell cultures were in-
cubated at 37°C in 5% CO2.  
Claudin-1 expression vectors and site-directed 
mutagenesis.  CLDN1 was cloned into mammalian 
expression vector pcDNA3.1/V5-His© as previously 
described (4). Site-directed mutagenesis was per-
formed on the claudin-1 sequence in the 
pcDNA3.1/V5-His vector using the Quikchange II 
site-directed mutagenesis kit (Stratagene, La Jolla, 
CA) to mutate the sites indicated in Table 1. For initial 
experiments attempting to attach CLDN1 to a nuclear 
localization signal, CLDN1 was then subcloned into 
the PdsRed2-Nuc vector (Clontech, Mountainview, 
CA). The correct sequence and orientation of all con-
structs was verified by direct DNA sequencing.  
Transfections. Cells were allowed to reach 
60-80% confluency within 48 hours of seeding. The 
cells were transfected with claudin-1 expression vec-
tors or empty vector controls, using Lipofectamine 
Plus (Gibco-BRL). After six hours of transfection, the 
medium was replaced with fresh serum-containing 
medium. For stable transfections, cells were treated Int. J. Med. Sci. 2009, 6 
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with 500μg/mL G418, clones were selected and ana-
lyzed for CLDN1 expression by confocal microscopy 
using a Zeiss Meta 510 confocal microscope (Zeiss, 
Thornwood, NY). 
Treatments. For PKC inhibition studies Gö 6983 
(Sigma, St. Louis, MO) was used at a concentration of 
1uM, and PMA (Cell Signaling, Beverly, MA) was 
used at a concentration of 200nM as previously de-
scribed (4). For vehicle controls, cells were treated 
with equivalent amounts of DMSO. PKA inhibitor 
(cell permeable, myristoylated Protein Kinase A In-
hibitor Amide 14-22, Calbiochem, San Diego, CA), 
was used at a concentration of 10μM for the indicated 
times. The PKA activator, forskolin (Sigma) was used 
at a concentration of 5 μM for the indicated times. 
Immunofluorescenct confocal microscopy. As 
previously described (4), for claudin-1 staining, cells 
were grown on glass slides, and allowed to reach 80% 
confluency. Cells were fixed using 95% methanol, 
washed and blocked with a fluorescent blocking 
buffer (0.2% Triton-X100, 0.2% BSA, 0.2%, Casein, 5% 
normal goat serum, 0.2% gelatin, 0.02% sodium azide) 
for 1 hour at room temperature. Incubation in 
claudin-1 primary antibody at 0.25μg/ml (ZYMED 
Laboratories, San Francisco, CA) was performed 
overnight at 4oC. The cells were washed again with 
PBS for 30 minutes, probed with secondary antibody 
(conjugated with Alexa fluor-488, Invitrogen, Carls-
bad, CA), then washed again with PBS, mounted in 
Pro-long Gold® (Invitrogen, Carlsbad, CA) with 
DAPI and then examined using confocal microscopy. 
Images were taken using a Zeiss Meta 510 confocal 
microscope.  
Western Analysis. β-tubulin (1:1000), Lamin-A 
(1:1000), Phospho- PKA (1:1000) and PKC substrate 
(1:200) antibodies were obtained from Cell Signaling 
(Beverly, MA). Claudin-1 antibody (1:1000) was ob-
tained from Zymed Laboratories (San Francisco, CA). 
Cells were grown to 80% confluency and then har-
vested on ice as previously described (4). Nuclear and 
cytoplasmic extracts were obtained according to 
manufacturer’s instructions using the NE-PER extrac-
tion kit (Pierce, Rockford, IL). Proteins were quanti-
tated using a Pierce BCA protein quantitation assay 
(Pierce). 50μg of each lysate was run out on 
SDS-PAGE 10% Tris-glycine Nu-PAGE gels (Invitro-
gen) and transferred onto 0.2 micron PVDF. The 
membranes were probed with antibodies and then 
visualized using the ECL system (Amersham Bio-
sceinces, Piscataway, NJ).  
For immunoprecipitation, 250μg of lysate was 
incubated with protein A/G agarose (Sigma) for 4 
hours to clear the lysate. The mixture was centrifuged 
gently, and the lysate was removed from the beads 
and placed into a new, siliconized microfuge tube. 
PKC substrate antibody was added at a ratio of 1:200, 
and the lysate and antibody were incubated with 
gentle rocking overnight at 4°C. Protein A/G agarose 
was then added for 6h, after which time the lysate was 
removed, and the agarose washed in RIPA three 
times. SDS-based sample buffer was used to remove 
the bound proteins from the agarose, and the entire 
mixture was subjected to Western analysis for 
claudin-1 as described above. 
Invasion Assays. Matrigel invasion assays were 
performed using transwell migration chambers 
(Corning life Sciences, Lowell, MA) as previously de-
scribed (21). Briefly, 8μM filters were coated with 
150μL of 80μg/mL reconstituted basement membrane 
(Matrigel®, Becton Dickinson, Franklin Lakes, NJ). 
Wild type or mutant claudin-1 expressing clones were 
serum starved for 16h, and 2 X 105 cells were seeded 
onto the filters. The total volume on the top of the 
filter was adjusted to 800μL of serum free medium 
and 800μL of medium containing 20% fetal calf serum 
was placed in the lower well to act as a chemoattrac-
tant. Cells were allowed to invade and adhere to the 
lower chamber, after which they were stained using 
crystal violet, and counted. All cell lines were assayed 
in triplicate.  
Statistics.  A Student’s t-test was performed 
when required in at least 3 independent experiments. 
Significance was designated as *p<0.05, **p<0.01. 
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